Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Not Confirmed
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
27-30 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
27-30 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
24 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/24/3047939/0/en/Anaptys-Announces-Stock-Repurchase-Plan.html
27 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/27/3034349/0/en/Anaptys-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html
27 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/27/3034343/0/en/Anaptys-Announces-Participation-in-March-Investor-Conferences.html
12 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/12/3024946/0/en/Anaptys-Announces-Rosnilimab-Achieved-Positive-Results-in-RA-Phase-2b-Trial-and-Highest-Ever-Reported-CDAI-LDA-Response-Over-6-Months.html
11 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/11/3024646/0/en/Anaptys-to-Announce-Top-line-Data-from-Phase-2b-Trial-of-Rosnilimab-a-PD-1-Depleter-and-Agonist-in-Rheumatoid-Arthritis-on-Feb-12-2025.html
03 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2025/02/03/3019868/0/en/Anaptys-to-Present-at-the-Guggenheim-SMID-Cap-Biotech-Conference.html
Details:
ANB030 (rosnilimab) is a subcutaneous PD-1 agonist antibody, which is being evaluated for the treatment of rheumatoid arthritis.
Lead Product(s): Rosnilimab
Therapeutic Area: Immunology Brand Name: ANB030
Study Phase: Phase IIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2025
Lead Product(s) : Rosnilimab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anaptys’ Rosnilimab Shows Positive RA Phase 2b Results, Highest CDAI LDA
Details : ANB030 (rosnilimab) is a subcutaneous PD-1 agonist antibody, which is being evaluated for the treatment of rheumatoid arthritis.
Product Name : ANB030
Product Type : Antibody
Upfront Cash : Inapplicable
February 12, 2025
Details:
ANB030 (rosnilimab) is a subcutaneous PD-1 agonist antibody, which is being evaluated for the treatment of rheumatoid arthritis.
Lead Product(s): Rosnilimab
Therapeutic Area: Immunology Brand Name: ANB030
Study Phase: Phase IIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 11, 2025
Lead Product(s) : Rosnilimab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anaptys to Reveal Rosnilimab Phase 2b RA Trial Data on Feb 12, 2025
Details : ANB030 (rosnilimab) is a subcutaneous PD-1 agonist antibody, which is being evaluated for the treatment of rheumatoid arthritis.
Product Name : ANB030
Product Type : Antibody
Upfront Cash : Inapplicable
February 11, 2025
Details:
Under the licensing agreement, Vanda will hold the exclusive rights for the development & commercialization of ANB019 (imsidolimab). It is being evaluated for treating Generalized Pustular Psoriasis.
Lead Product(s): Imsidolimab
Therapeutic Area: Dermatology Brand Name: ANB019
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Vanda Pharmaceuticals
Deal Size: $45.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement February 03, 2025
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Vanda Pharmaceuticals
Deal Size : $45.0 million
Deal Type : Licensing Agreement
Vanda, Anaptys Sign Global License for IL-36R Antagonist Imsidolimab
Details : Under the licensing agreement, Vanda will hold the exclusive rights for the development & commercialization of ANB019 (imsidolimab). It is being evaluated for treating Generalized Pustular Psoriasis.
Product Name : ANB019
Product Type : Antibody
Upfront Cash : $10.0 million
February 03, 2025
Details:
ANB032 is a BTLA agonist antibody candidate, which is being evaluated for the treatment of patients with atopic dermatitis eczema.
Lead Product(s): ANB032
Therapeutic Area: Dermatology Brand Name: ANB032
Study Phase: Phase IIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 11, 2024
Lead Product(s) : ANB032
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anaptys Announces Phase 2b Trial of ANB032 Did Not Meet Endpoints in Atopic Dermatitis
Details : ANB032 is a BTLA agonist antibody candidate, which is being evaluated for the treatment of patients with atopic dermatitis eczema.
Product Name : ANB032
Product Type : Antibody
Upfront Cash : Inapplicable
December 11, 2024
Details:
Jemperli (dostarlimab) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Lead Product(s): Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Brand Name: Jemperli
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Sagard Healthcare Partners
Deal Size: $50.0 million Upfront Cash: $50.0 million
Deal Type: Agreement September 05, 2024
Lead Product(s) : Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Sagard Healthcare Partners
Deal Size : $50.0 million
Deal Type : Agreement
Anaptys to Receive $50 Million from Amended Agreement with Sagard for Jemperli Royalties
Details : Jemperli (dostarlimab) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Product Name : Jemperli
Product Type : Antibody
Upfront Cash : $50.0 million
September 05, 2024
Details:
ANB019 (imsidolimab) is a fully humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, that is being developed for the treatment of GPP.
Lead Product(s): Imsidolimab
Therapeutic Area: Dermatology Brand Name: ANB019
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 05, 2024
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anaptys Reports Positive Results from GEMINI-2 Phase 3 Trial of Imsidolimab in Psoriasis
Details : ANB019 (imsidolimab) is a fully humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, that is being developed for the treatment of GPP.
Product Name : ANB019
Product Type : Antibody
Upfront Cash : Inapplicable
September 05, 2024
Details:
The net proceeds will be used to fund the clinical development of the company's lead product ANB032 BTLA agonist antibody, which is being evaluated for the treatment of Atopic Dermatitis Eczema.
Lead Product(s): ANB032
Therapeutic Area: Dermatology Brand Name: ANB032
Study Phase: Phase IIProduct Type: Antibody
Sponsor: TD Cowen
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 14, 2024
Lead Product(s) : ANB032
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : TD Cowen
Deal Size : $100.0 million
Deal Type : Public Offering
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
Details : The net proceeds will be used to fund the clinical development of the company's lead product ANB032 BTLA agonist antibody, which is being evaluated for the treatment of Atopic Dermatitis Eczema.
Product Name : ANB032
Product Type : Antibody
Upfront Cash : Undisclosed
August 14, 2024
Details:
ANB019 (imsidolimab) is a fully humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, that is being developed for the treatment of GPP.
Lead Product(s): Imsidolimab
Therapeutic Area: Dermatology Brand Name: ANB019
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 10, 2023
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ANB019 (imsidolimab) is a fully humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, that is being developed for the treatment of GPP.
Product Name : ANB019
Product Type : Antibody
Upfront Cash : Inapplicable
September 10, 2023
Details:
JEMPERLI (dostarlimab-gxly) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Lead Product(s): Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Brand Name: Jemperli
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: GSK
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 31, 2023
Lead Product(s) : Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JEMPERLI (dostarlimab-gxly) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Product Name : Jemperli
Product Type : Antibody
Upfront Cash : Inapplicable
July 31, 2023
Details:
ANB030 (Rosnilimab), its investigational wholly owned PD-1 agonist, demonstrates best-in-class activity in vitro with superior inhibition of T cell proliferation, reduction in inflammatory cytokine secretion (Th1, Th2, Th17) and depletion of PD-1+ T cells.
Lead Product(s): Rosnilimab
Therapeutic Area: Dermatology Brand Name: ANB030
Study Phase: Phase IIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 01, 2023
Lead Product(s) : Rosnilimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
Details : ANB030 (Rosnilimab), its investigational wholly owned PD-1 agonist, demonstrates best-in-class activity in vitro with superior inhibition of T cell proliferation, reduction in inflammatory cytokine secretion (Th1, Th2, Th17) and depletion of PD-1+ T cell...
Product Name : ANB030
Product Type : Antibody
Upfront Cash : Inapplicable
May 01, 2023
ABOUT THIS PAGE